Potassium and Related Disorders

TopicLeading institutions, researchers & key papers

This cluster of papers focuses on the management of hyperkalemia, particularly in patients with kidney diseases. It covers various aspects such as the use of renin-angiotensin-aldosterone system inhibitors, potassium homeostasis, and the effectiveness of treatments like sodium zirconium cyclosilicate and patiromer. Additionally, it explores the association of hyperkalemia with conditions like chronic kidney disease, heart failure, and gastrointestinal adverse events.

253

Works

IDs:OpenAlex

How has Potassium and Related Disorders's publication output changed over time?

ScholarIQpublication output · 2009–2021

Output grew0% over the shown period — from 1 works in 2009 to 1 in 2021.

2009201020112013201420152017201820192021

What are the most-cited papers on Potassium and Related Disorders?

ScholarIQmost cited works

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

Rajiv Agarwal, Gerasimos Filippatos, Bertram Pitt, Stefan D. Anker, Peter Rossing, Amer Joseph, Peter Kolkhof, Christina Nowack, Martin Gebel, Luís M. Ruilope, George L. Bakris, FIDELIO-DKD and FIGARO-DKD investigators

European Heart Journal. 20211,234 CitationsOPEN ACCESS

Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors

Matthew R. Weir, George L. Bakris, David A. Bushinsky, Martha Mayo, Dahlia Garza, Yuri Stasiv, Janet Wittes, Heidi Christ‐Schmidt, Lance Berman, Bertram Pitt

New England Journal of Medicine. 2014668 CitationsOPEN ACCESS

The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease

Lisa M. Einhorn, Min Zhan, Van Doren Hsu, Lori D. Walker, Maureen F. Moen, Stephen L. Seliger, Matthew R. Weir, Jeffrey C. Fink

S4210206803. 2009647 CitationsOPEN ACCESS

Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Catherine M. Clase, Juan Jesús Carrero, David H. Ellison, Morgan E. Grams, Brenda R. Hemmelgarn, Meg Jardine, Csaba P. Kövesdy, Gregory Kline, Gregor Lindner, Gregorio T. Obrador, Biff F. Palmer, Michael Cheung, David C. Wheeler, Wolfgang C. Winkelmayer, Roberto Pecoits‐Filho, Gloria Ashuntantang, Stephan J. L. Bakker, George L. Bakris, Sunil Bhandari, Emmanuel A. Burdmann, Katrina L. Campbell, David M. Charytan, Deborah J. Clegg, Lílian Cuppari, David Goldsmith, Stein Hallan, Jiang He, Charles A. Herzog, Melanie P. Hoenig, Ewout J. Hoorn, Jens Leipziger, Amanda K. Leonberg‐Yoo, Edgar V. Lerma, Jose Ernesto Lopez-Almaraz, Jolanta Małyszko, Johannes F.E. Mann, Matti Marklund, Alicia A. McDonough, Masahiko Nagahama, Sankar D. Navaneethan, Bertram Pitt, Oleh Pochynyuk, Thyago Proença de Moraes, Zubaid Rafique, Bruce Robinson, Simon D. Roger, Patrick Rossignol, Adam J. Singer, Andrew Smyth, Manish M. Sood, Michael Walsh, Matthew R. Weir, Charles S. Wingo

Kidney International. 2019491 CitationsOPEN ACCESS

Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial

Bertram Pitt, Stefan D. Anker, David A. Bushinsky, Dalane W. Kitzman, Faı̈ez Zannad, I‐Zu Huang, on behalf of the PEARL-HF Investigators

European Heart Journal. 2011442 CitationsOPEN ACCESS